Psilocin formulations of psilocin mucate with improved stability, physical properties and/or handling characteristics, as well as enhanced pharmacologic activity, pharmacokinetic parameters and safety characteristics as compared to psilocin or psilocybin and methods for their use are provided.

The invention relates to a crystalline diethylamine tetrathiomolybdate salt (DEA-TTM). The invention also relates to methods for producing the crystalline DEA-TTM salt of the invention. The invention also relates to pharmaceutical compositions comprising the crystalline DEA-TTM salt of the invention. The invention also relates to the use of the crystalline DEA-TTM salt of the invention in the treatment of the human or animal body, in particular its use in treatment of a condition requiring reduced metabolism of an organ or the whole body of a patient, by administering to a patient in need thereof a therapeutically effective amount of the crystalline DEA-TTM salt.

The invention relates to a crystalline diethylamine tetrathiomolybdate salt (DEA-TTM). The invention also relates to methods for producing the crystalline DEA-TTM salt of the invention. The invention also relates to pharmaceutical compositions comprising the crystalline DEA-TTM salt of the invention. The invention also relates to the use of the crystalline DEA-TTM salt of the invention in the treatment of the human or animal body, in particular its use in treatment of a condition requiring reduced metabolism of an organ or the whole body of a patient, by administering to a patient in need thereof a therapeutically effective amount of the crystalline DEA-TTM salt.

The invention relates to a crystalline diethylamine tetrathiomolybdate salt (DEA-TTM). The invention also relates to methods for producing the crystalline DEA-TTM salt of the invention. The invention also relates to pharmaceutical compositions comprising the crystalline DEA-TTM salt of the invention. The invention also relates to the use of the crystalline DEA-TTM salt of the invention in the treatment of the human or animal body, in particular its use in treatment of a condition requiring reduced metabolism of an organ or the whole body of a patient, by administering to a patient in need thereof a therapeutically effective amount of the crystalline DEA-TTM salt.

Disclosed are methods for separating, recovering, and purifying CBGA, CBDVA, THCVA, CBCVA, and CBCA from dewatered and desolventized crude complex extracts or mixtures of metabolites, cannabinoids, and Cannabis phytochemicals. The methods comprise solubilizing the extracts or mixtures of cannabinoids in a selected solvent, adding a selected amine to precipitate a CBGA-amine or CBDVA-amine or THCVA-amine or CBCVA-amine or CBCA-amine salt therefrom, dissolving the recovered amine salt in a selected solvent, and adding a selected antisolvent to recrystallize a purified amine salt therefrom. The recrystallized amine salt may be decarboxylated to form a mixture of CBG or CBDV or THCV or CBCV or CBC and amine. The cannabinoid and amine mixture may be acidified to separate the amine from CBG or CBDV or THCV or CBCV or CBC. The recovered CBG or CBDV or THCV or CBCV or CBC may then be concentrated.

The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.

Disclosed in the present invention is a method for preparing a tertiary amine by using a secondary amine as a raw material. The method comprises a step of reacting a secondary amine that serves as a raw material with an acid to generate a proton-type ionic liquid, and a step of reacting the proton-type ionic liquid with an aldehyde under the action of a reducing agent to generate a tertiary amine. The secondary amine is an aliphatic secondary amine and/or an aromatic secondary amine and/or a cyclic secondary amine; the acid is selected from one of or a combination of several of an organic carboxylic acid and an inorganic acid; the aldehyde is a monoaldehyde, a dialdehyde or an aldehyde polymer; and the reducing agent is selected from one of or a combination of several of formic acid, sodium formate, oxalic acid, sodium oxalate and triphenylsilane.

Disclosed in the present invention is a method for preparing a tertiary amine by using a secondary amine as a raw material. The method comprises a step of reacting a secondary amine that serves as a raw material with an acid to generate a proton-type ionic liquid, and a step of reacting the proton-type ionic liquid with an aldehyde under the action of a reducing agent to generate a tertiary amine. The secondary amine is an aliphatic secondary amine and/or an aromatic secondary amine and/or a cyclic secondary amine; the acid is selected from one of or a combination of several of an organic carboxylic acid and an inorganic acid; the aldehyde is a monoaldehyde, a dialdehyde or an aldehyde polymer; and the reducing agent is selected from one of or a combination of several of formic acid, sodium formate, oxalic acid, sodium oxalate and triphenylsilane.

The disclosure provides a process for preparing solid tri(C.sub.1-C.sub.4 alkyl)ammonium dihydrogen phosphates such as triethylammonium dihydrogen phosphate, in high yield, and in a free-flowing particulate form. The solid product advantageously possesses less than about 1500 ppm of aprotic organic solvents, less than about 1500 ppm of C.sub.1-C.sub.5 alkanols, and less than about 500 ppm of water, as determined by Karl Fischer titration.

The disclosure provides a process for preparing solid tri(C.sub.1-C.sub.4 alkyl)ammonium dihydrogen phosphates such as triethylammonium dihydrogen phosphate, in high yield, and in a free-flowing particulate form. The solid product advantageously possesses less than about 1500 ppm of aprotic organic solvents, less than about 1500 ppm of C.sub.1-C.sub.5 alkanols, and less than about 500 ppm of water, as determined by Karl Fischer titration.